We examined the effect of PLK1 inhibition via treatment with onvansertib, an oral available PLK1 inhibitor, alone or in combination with paclitaxel on mouse xenograft models of the mesenchymal breast cancer SUM159. This evidence concerns the gene PLK1 and breast cancer.